drugset

drugset / Trial / NCT04979130

Comparing Semaglutide Versus Placebo on Intestinal Barrier Function in Type 2 Diabetes Mellitus (SIB)

NCT04979130 ↗

Phase 4 Completed 69 enrolled University of Colorado, Denver Novo Nordisk A/S · collab

RandomizedParallel-groupTriple-blindBasic science

Summary

This study plans to learn more about the effect of semaglutide once weekly on intestinal permeability in individuals with type 2 diabetes.

Timeline

Start: 2022-01-01
Primary completion: 2024-10-16
Completion: 2024-10-16

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Semaglutide	Peptide	1 mg	Subcutaneous

Indications